More than three-quarters of the multiple myeloma patients treated with an experimental CAR-T therapy from Johnson & Johnson are alive at least one year without their cancer worsening, according to updated clinical trial results presented Saturday at the annual meeting of the American Society of Hematology.
Tumor responses to the J&J bespoke cell treatment were already known to be among the highest reported in multiple myeloma — stronger than a competing CAR-T from Bristol Myers Squibb and Bluebird Bio.
The new data presented Saturday also show the potential for the J&J therapy, ciltacabtagene autoleucel or cilta-cel, to be the longest-lasting treatment that could help patients live longer. The enhanced efficacy, however, comes with greater side effects, most notably late-onset and persistent neurotoxicity that some patients reported.
About the Author Reprints
